

Carcinoid Syndrome- Pipeline Insight, 2019

<https://marketpublishers.com/r/C4430735B7BEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: C4430735B7BEN

Abstracts

This report can be delivered to the clients within 24 Hours

"Carcinoid Syndrome- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Carcinoid Syndrome pipeline landscape is provided which includes the disease overview and Carcinoid Syndrome treatment guidelines. The assessment part of the report embraces, in depth Carcinoid Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Carcinoid Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Carcinoid Syndrome Understanding

Carcinoid syndrome occurs when a rare cancerous tumor called a carcinoid tumor secretes certain chemicals into your bloodstream, causing a variety of signs and symptoms. Carcinoid tumors occur most commonly in the gastrointestinal tract or lungs, including stomach, small intestine, appendix, colon and rectum. Carcinoid syndrome typically occurs in people who have carcinoid tumors that are advanced. Treatment for carcinoid syndrome usually involves treating the cancer. The symptoms of carcinoid syndrome include episodes of warmth and redness of the face, head and upper chest; diarrhea; marked changes in blood pressure (usually hypotension, a decrease in blood pressure); asthmatic-like wheezing; weight loss or gain; malnutrition; dehydration; weakness; muscle and joint aching; and peptic ulcer. When tumors affect organs other than the gastrointestinal tract, such as the ovaries, carcinoid syndrome can occur in the absence of liver metastases.

Carcinoid Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Carcinoid Syndrome targeted therapeutics development with respective active and dormant or discontinued projects. Carcinoid Syndrome pipeline report covers 12+ companies. Some of the key players include Aquestive Therapeutics (AQST-305), QLT USA (Atrigel-Octreotide), Mateon Therapeutics (Fosbretabulin), etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Carcinoid Syndrome Analytical Perspective by DelveInsight

In-depth Carcinoid Syndrome Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Carcinoid Syndrome Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report

The Carcinoid Syndrome report provides an overview of therapeutic pipeline activity for Carcinoid Syndrome across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Carcinoid Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Carcinoid Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Carcinoid Syndrome

Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Carcinoid Syndrome to formulate effective R&D strategies

Assess challenges and opportunities that influence Carcinoid Syndrome R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each project along with key milestones

Devise Carcinoid Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Carcinoid Syndrome to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Contents

1. REPORT INTRODUCTION

2. CARCINOID SYNDROME

- 2.1. Carcinoid Syndrome Disease Overview
- 2.2. Carcinoid Syndrome History
- 2.3. Carcinoid Syndrome Symptoms
- 2.4. Carcinoid Syndrome Causes
- 2.5. Carcinoid Syndrome Pathophysiology
- 2.6. Carcinoid Syndrome Diagnosis
 - 2.6.1. Diagnostic Guidelines

3. CARCINOID SYNDROME CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

4. CARCINOID SYNDROME - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
 - 4.1.1. Carcinoid Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
 - 4.1.1.1. Assessment Summary
 - 4.1.2. Carcinoid Syndrome Collaboration Deals
 - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
 - 4.1.2.2. Carcinoid Syndrome Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
 - 4.2.1. Assessment by Phase of Development
 - 4.2.2. Assessment by Product Type (Mono / Combination)
 - 4.2.2.1. Assessment by Stage and Product Type
 - 4.2.3. Assessment by Route of Administration
 - 4.2.3.1. Assessment by Stage and Route of Administration
 - 4.2.4. Assessment by Molecule Type
 - 4.2.4.1. Assessment by Stage and Molecule Type
 - 4.2.5. Assessment by MOA
 - 4.2.5.1. Assessment by Stage and MOA

5. CARCINOID SYNDROME PIPELINE THERAPEUTICS

- 5.1. Late Stage Products (Phase-III)
 - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
 - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
 - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
 - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

6. CARCINOID SYNDROME -PRODUCTS ANALYSIS

- 6.1. Product Profiles
 - 6.1.1. AQST-305: Aquestive Therapeutics
 - 6.1.1.1. Product Description
 - 6.1.1.1.1. Product Overview
 - 6.1.1.1.2. Mechanism of Action
 - 6.1.1.2. Research and Development
 - 6.1.1.2.1. Clinical Studies
 - 6.1.1.2.1.1. Detailed Study Description
 - 6.1.1.2.1.2. Study Results
 - 6.1.1.2.1.3. Clinical Trials: Tabular View
 - 6.1.1.3. Product Development Activities
 - 6.1.1.3.1. Tabulated Product Summary
 - 6.1.1.3.1.1. General Description Table
 - 6.1.2. Atrigel-Octreotide: QLT USA
 - 6.1.2.1. Product Description
 - 6.1.2.1.1. Product Overview
 - 6.1.2.1.2. Mechanism of Action
 - 6.1.2.2. Research and Development
 - 6.1.2.2.1. Clinical Studies
 - 6.1.2.2.1.1. Detailed Study Description
 - 6.1.2.2.1.2. Study Results
 - 6.1.2.2.1.3. Clinical Trials: Tabular View
 - 6.1.2.3. Product Development Activities
 - 6.1.2.3.1. Tabulated Product Summary
 - 6.1.2.3.1.1. General Description Table
 - 6.1.3. Fosbretabulin: Mateon Therapeutics

- 6.1.3.1. Product Description
 - 6.1.3.1.1. Product Overview
 - 6.1.3.1.2. Mechanism of Action
- 6.1.3.2. Research and Development
 - 6.1.3.2.1. Clinical Studies
 - 6.1.3.2.1.1. Detailed Study Description
 - 6.1.3.2.1.2. Study Results
 - 6.1.3.2.1.3. Clinical Trials: Tabular View
- 6.1.3.3. Product Development Activities
 - 6.1.3.3.1. Tabulated Product Summary
 - 6.1.3.3.1.1. General Description Table

To be continued in the report.....

7. RECENT TECHNOLOGIES

8. CARCINOID SYNDROME KEY COMPANIES

- 8.1. Mateon Therapeutics
- 8.2. Midatech Pharma
- 8.3. Endo Pharmaceuticals Solutions
- 8.4. Aquestive Therapeutics
- 8.5. Evlutec
- 8.6. Exelixis
- 8.7. AnorMED
- 8.8. CASI Pharmaceuticals
- 8.9. GP Pharm
- 8.10. Amgen
- 8.11. QLT USA
- 8.12. Ipsen

9. CARCINOID SYNDROME KEY PRODUCTS

- 9.1. Fosbretabulin
- 9.2. BIM 23A760
- 9.3. Octreotide sustained release
- 9.4. VP 003
- 9.5. AQST-305
- 9.6. Research programme: serotonin/histamine antagonists
- 9.7. Cabozantinib
- 9.8. Atiprimod

- 9.9. 2-Methoxyestradiol
- 9.10. Octreotide depot
- 9.11. Panitumumab
- 9.12. Atrigel-Octreotide

10. DORMANT AND DISCONTINUED PRODUCTS

- 10.1. Dormant Products
 - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
 - 10.2.1. Reasons for the discontinuation

11. CARCINOID SYNDROME - UNMET NEEDS

12. CARCINOID SYNDROME - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

- 14.1. Secondary Research
- 14.2. Expert Panel Validation

List Of Tables

LIST OF TABLES

- Table 1. Carcinoid Syndrome Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Carcinoid Syndrome Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Carcinoid Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Carcinoid Syndrome Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

KEY COMPANIES

Novartis
Abbott
Karus Pharmaceuticals
QLT USA

Ipsen
Lexicon Pharmaceuticals
Mateon Therapeutics
Midatech Pharma
Valera Pharmaceuticals
Aquestive Therapeutics
Evolutec
Exelixis
AnorMED
CASI Pharmaceuticals
GP Pharm
Amgen
Eli Lilly

I would like to order

Product name: Carcinoid Syndrome- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/C4430735B7BEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4430735B7BEN.html>